TIAA CREF Investment Management LLC purchased a new position in Pulse Biosciences, Inc (NASDAQ:PLSE) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 24,702 shares of the company’s stock, valued at approximately $853,000. TIAA CREF Investment Management LLC owned 0.17% of Pulse Biosciences at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PLSE. Schwab Charles Investment Management Inc. acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $529,000. Rhumbline Advisers acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $325,000. Bank of New York Mellon Corp acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $897,000. Wells Fargo & Company MN grew its holdings in shares of Pulse Biosciences by 21,473.2% in the 2nd quarter. Wells Fargo & Company MN now owns 53,933 shares of the company’s stock worth $1,862,000 after acquiring an additional 53,683 shares during the period. Finally, Teachers Advisors LLC acquired a new stake in shares of Pulse Biosciences in the 2nd quarter worth approximately $566,000. Institutional investors and hedge funds own 9.79% of the company’s stock.
In related news, major shareholder Robert W. Duggan bought 22,901 shares of Pulse Biosciences stock in a transaction that occurred on Thursday, October 19th. The shares were purchased at an average price of $22.79 per share, with a total value of $521,913.79. Following the purchase, the insider now owns 5,820,513 shares in the company, valued at $132,649,491.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Robert W. Duggan bought 2,000,000 shares of Pulse Biosciences stock in a transaction that occurred on Sunday, September 24th. The stock was bought at an average cost of $15.02 per share, for a total transaction of $30,040,000.00. Following the purchase, the insider now owns 5,797,612 shares in the company, valued at approximately $87,080,132.24. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 2,466,429 shares of company stock worth $36,893,301. 6.70% of the stock is owned by corporate insiders.
Shares of Pulse Biosciences, Inc (NASDAQ PLSE) opened at $30.33 on Monday. Pulse Biosciences, Inc has a 52 week low of $5.20 and a 52 week high of $39.50.
Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Tuesday, November 7th. The company reported ($0.52) earnings per share (EPS) for the quarter.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/11/13/24702-shares-in-pulse-biosciences-inc-plse-purchased-by-tiaa-cref-investment-management-llc.html.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences, Inc (NASDAQ:PLSE).
Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.